Cargando…

Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer

BACKGROUND: To evaluate the relationship between body composition and the oncological outcome of androgen deprivation therapy (ADT), we investigated whether body composition features including the psoas muscle may be predictive factors of ADT. METHODS: This study enrolled patients with hormone-naïve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kashiwagi, Eiji, Shiota, Masaki, Masaoka, Hiroyuki, Imada, Kenjiro, Monji, Keisuke, Takeuchi, Ario, Inokuchi, Junichi, Tatsugami, Katsunori, Eto, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Pacific Prostate Society 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125377/ https://www.ncbi.nlm.nih.gov/pubmed/32257974 http://dx.doi.org/10.1016/j.prnil.2019.11.002

Ejemplares similares

Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy
por: Shiota, Masaki, et al.
Publicado: (2018)

Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone
por: Akitake, Naoko, et al.
Publicado: (2018)

Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer
por: Hirata, Yu, et al.
Publicado: (2019)

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants
por: Shiota, Masaki, et al.
Publicado: (2018)

Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy
por: Shiota, Masaki, et al.
Publicado: (2015)

Equol inhibits prostate cancer growth through degradation of androgen receptor by S‐phase kinase‐associated protein 2
por: Itsumi, Momoe, et al.
Publicado: (2016)

Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide
por: Kashiwagi, Eiji, et al.
Publicado: (2022)

Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors
por: Matsumoto, Takashi, et al.
Publicado: (2021)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
por: Yamada, Shigetomo, et al.
Publicado: (2022)

Gene amplification of YB‐1 in castration‐resistant prostate cancer in association with aberrant androgen receptor expression
por: Shiota, Masaki, et al.
Publicado: (2020)

Validation of user-friendly models predicting extracapsular extension in prostate cancer patients
por: Blas, Leandro, et al.
Publicado: (2023)

An oral first‐in‐class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer
por: Ushijima, Miho, et al.
Publicado: (2022)

The Role of Nuclear Receptors in Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2019)

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer
por: Chikamatsu, Sotaro, et al.
Publicado: (2022)

Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade
por: Tanaka, Kentaro, et al.
Publicado: (2018)

Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old
por: Blas, Leandro, et al.
Publicado: (2021)

Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone
por: Shiota, Masaki, et al.
Publicado: (2019)

Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy
por: Shiota, Masaki, et al.
Publicado: (2016)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
por: Inokuchi, Junichi, et al.
Publicado: (2019)

Doxycycline induces apoptosis via ER stress selectively to cells with a cancer stem cell-like properties: importance of stem cell plasticity
por: Matsumoto, Takashi, et al.
Publicado: (2017)

Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
por: Takeuchi, Ario, et al.
Publicado: (2020)

Antiandrogenic Effects of a Polyphenol in Carex kobomugi through Inhibition of Androgen Synthetic Pathway and Downregulation of Androgen Receptor in Prostate Cancer Cell Lines
por: Kudo, Yudai, et al.
Publicado: (2022)

Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician’s Perspective
por: Matsumoto, Takashi, et al.
Publicado: (2022)

Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence
por: Izumi, Koji, et al.
Publicado: (2016)

Current Status and Future Perspective on the Management of Lymph Node-Positive Prostate Cancer after Radical Prostatectomy
por: Shiota, Masaki, et al.
Publicado: (2022)

Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data
por: Blas, Leandro, et al.
Publicado: (2022)

Cyclophosphamide-Induced Tolerance in Allogeneic Transplantation: From Basic Studies to Clinical Application
por: Kato, Koji, et al.
Publicado: (2020)

Genetic variations predicting progression with docetaxel and novel androgen‐receptor pathway inhibitors
por: Shiota, Masaki, et al.
Publicado: (2023)

WHO SHOULD RECEIVE NOVEL HORMONAL THERAPY WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER?
por: Omrčen, Tomislav
Publicado: (2019)

Successful management of cryptococcosis of the bilateral adrenal glands and liver by unilateral adrenalectomy with antifungal agents: a case report
por: Matsuda, Yayoi, et al.
Publicado: (2011)

Radiotherapy plus androgen deprivation therapy for prostate‐specific antigen persistence in lymph node–positive prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2022)

Potential overtreatment among men aged 80 years and older with localized prostate cancer in Japan
por: Masaoka, Hiroyuki, et al.
Publicado: (2017)

Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier
por: Etheridge, Tyler, et al.
Publicado: (2019)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel
por: Jiménez, Natalia, et al.
Publicado: (2022)

Neurocognitive effects of androgen deprivation therapy and new hormonal agents in a sample of patients with metastatic prostate cancer
por: Ihrig, Andreas, et al.
Publicado: (2023)

Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis
por: Fiorica, Francesco, et al.
Publicado: (2022)

Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis
por: Maiorano, B.A., et al.
Publicado: (2022)

Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials
por: Kawano, Takahito, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p1ppo13mjkf7kq1d1d6mhg8umf